Y-Mabs Therapeutics Profit Margin

Y-Mabs Therapeutics (YMAB) currently reports a profit margin of -26.03% as of June 2025. That compares with -28.44% in the prior-year period — up 8.5% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Y-Mabs Therapeutics's profit margin history and peer comparisons.

Y-Mabs Therapeutics's profit margin increased from -28.44% to -26.03% — a 8.5% year-over-year increase (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Y-Mabs Therapeutics's profit margin of -26.03% is lower than the Healthcare sector average of 15.58%. That is roughly 267.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Y-Mabs Therapeutics's current -26.03% should be judged against Healthcare norms (sector average: 15.58%) and against YMAB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -26.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Y-Mabs Therapeutics, and consider following YMAB for alerts when major investors trade the stock.